Form 4: Anebulo Pharmaceuticals CEO Acquires Stock Options
SEC Form 4 Filing
Richard Anthony Cunningham, CEO of Anebulo Pharmaceuticals, acquired stock options for 316,352 shares at an exercise price of $1.02 on April 4, 2025, according to a Form 4 filing.
Summary
- Richard Anthony Cunningham, the CEO of Anebulo Pharmaceuticals, filed a Form 4 disclosing a transaction involving derivative securities.
- On April 4, 2025, Cunningham acquired stock options for 316,352 shares of Anebulo Pharmaceuticals common stock.
- The exercise price for these options is $1.02 per share.
- One-sixteenth of the options vested immediately on April 4, 2025, and the remainder will vest in equal quarterly installments until January 15, 2029, contingent upon continued service to the company.
- The options expire on April 3, 2035.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a routine disclosure of executive compensation. The grant itself can be seen as mildly positive, reflecting confidence, but it's not a major event.
Positives
- The CEO's acquisition of stock options could be seen as a positive sign, indicating confidence in the company's future performance.
Risks
- The vesting of the options is contingent upon the CEO's continued service, creating a potential risk if the CEO were to leave the company before full vesting.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry.
- The vesting schedule and exercise price would need to be compared to similar grants at comparable companies to assess their competitiveness.
- Companies like Alkermes, Biohaven, and Sage Therapeutics also use stock options as part of their executive compensation.
Stakeholder Impact
- The stock option grant could potentially incentivize the CEO to improve company performance, benefiting shareholders.
- Employees may view the grant as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 04/04/2025 | Date of the stock option grant and initial vesting of one-sixteenth of the shares. |
| 01/15/2029 | Date of final vesting installment. |
| 04/03/2035 | Expiration date of the stock options. |
| 04/07/2025 | Date of Form 4 filing. |
Keywords
stock options, Form 4, Anebulo Pharmaceuticals, Richard Cunningham, CEO, derivative securities, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.